Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Liquid Immunogenic Fiducial Eluter (LIFE) for Cervical Cancer Treatment

Award Number: R41CA268623
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2022
PERIOD OF PERFORMANCE END DATE: 04/30/2024

Group Awards By:

View Award Description

Liquid Immunogenic Fiducial Eluter (LIFE) for Cervical Cancer Treatment - Project Summary Current treatment options for advanced cervical cancer are limited, with a 5-year overall survival rate of 17%. In the USA, pervasive disparities remain in access to treatment and mortality, disproportionately affecting African American and Latino populations. Innovative therapeutic approaches for metastatic disease that can increase access to care and reduce disparities are greatly needed. To meet this need, in this project, Nanocan Therapeutics Corporation in collaboration with Johns Hopkins University, will develop innovative technology that can extend the use of local radiotherapy (RT) from palliation to distant control of metastatic cervical cancer with substantially reduced treatment time and cost, facilitating access to care and reducing disparities. The new technology, which Nanocan has licensed from Brigham and Women’s Hospital at Harvard Medical School is a Liquid Immunotherapeutic Fiducial Eluter (LIFE) gel that can be easily administered locally and works in conjunction with hypo-fractionated radiotherapy for treatment of patients with advanced cervical cancer. Preliminary studies show that the use of the biocompatible/biodegradable LIFE gel technology can cause regression of both treated (local) and distant untreated/metastatic tumors and enable development of immunologic memory controlling disease for a long time. This Phase 1 STTR project focuses on optimizing efficacy and safety when employing the LIFE gel with HFRT in metastatic cervical cancer models setting. The results will set the stage for the first clinical trial. Innovative advantages of the LIFE gel include major potential to overcome immunosuppression due to sustained delivery, minimal systemic/overlapping toxicities, simple short treatment regimen, and providing imaging contrast for precision RT. The highest clinical impact of the LIFE gel technology approach is anticipated in significantly improved survival of advanced cervical cancer patients. Preliminary studies also show that this can provide a substantially cheaper alternative to systemic treatment and replace the intensive regimens over months to a short intervention, which will create significant opportunities for better global access to cancer care, and reduce cancer disparities.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	NANOCAN THERAPEUTICS CORPORATION	900 NEW HAMPSHIRE AVE NW	WASHINGTON	DC	20037	DISTRICT OF COLUMBIA	USA	Cancer Treatment Research	000	1	7/19/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	NANOCAN THERAPEUTICS CORPORATION	103 CARNEGIE CTR STE 300	PRINCETON	NJ	08540	MERCER	USA	Cancer Treatment Research	000	1	10/21/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $400,000 )
2022	2022	NANOCAN THERAPEUTICS CORPORATION	103 CARNEGIE CTR STE 300	PRINCETON	NJ	08540	MERCER	USA	Cancer Treatment Research	000	1	4/13/2022	NEW	$400,000
														Subtotal = $400,000

Grand Total All Awards = $400,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Liquid Immunogenic Fiducial Eluter (LIFE) for Cervical Cancer Treatment

Award Number: R41CA268623

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2022

PERIOD OF PERFORMANCE END DATE: 04/30/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer